Skip to main content

Advertisement

SpringerLink
Log in

Clinical benefit of trabectedin in uterine adenosarcoma

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Uterine adenosarcoma is an extremely rare uterine malignancy, and the utility of chemotherapy in this disease is not well defined. This study assessed the safety and efficacy of trabectedin in patients with recurrent/metastatic uterine adenosarcoma with sarcomatous overgrowth. A retrospective search of a prospectively maintained database was performed to identify patients with adenosarcoma treated with trabectedin between 2010 and 2012, within a compassionate use trial. Three patients with recurrent/metastatic uterine adenosarcoma treated with trabectedin were identified. All three patients tolerated the drug well. Two patients obtained prolonged clinical benefit from treatment, one having received 17 cycles and another 11 cycles of therapy. Trabectedin is well tolerated and has clinical activity in recurrent/metastatic uterine adenosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Clement PB, Scully RE. Müllerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of mullerian mixed tumor. Cancer. 1974;34:1138–49.

    Article  PubMed  CAS  Google Scholar 

  2. Andrade LA, Derchain SF, Vial JS, Alvarenga M. Mullerian adenosarcoma of the uterus in adolescents. Int J Gynaecol Obstet. 1992;38(2):119–23.

    Article  PubMed  CAS  Google Scholar 

  3. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a gynecologic oncology group clinicopathologic study of 31 cases. Int Gynecol Pathol. 1992;11(2):75–88.

    Article  CAS  Google Scholar 

  4. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363–81.

    Article  PubMed  CAS  Google Scholar 

  5. Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: a case report, review of the literature, and management discussion. Gynecol Oncol. 2009;115(3):472–5.

    Article  PubMed  Google Scholar 

  6. Carmen MG, Lovett D, Goodman A. A case of Müllerian adenosarcoma of the uterus treated with liposomal doxorubicin. Gynecol Oncol. 2002;88:456–8.

    Article  Google Scholar 

  7. Roman LD, Mitchell MF, Tornos C, Glover A, Kavanagh JJ. Dedifferentiated extrauterine adenosarcoma responsive to chemotherapy. Gynecol Oncol. 1993;49:389–94.

    Article  PubMed  CAS  Google Scholar 

  8. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010;10(2):249–60.

    Article  PubMed  CAS  Google Scholar 

  9. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890–9.

    Article  PubMed  CAS  Google Scholar 

  10. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576–84.

    Article  PubMed  Google Scholar 

  11. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480–90.

    Article  PubMed  CAS  Google Scholar 

  12. Grosso F, D’Incalci M, Cartoafa M, Nieto A, Fernandez-Teruel C, Alfaro V, Lardelli P, Roy E, Gomez J, Kahatt C, Soto-Matos, Judson I. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol. 2012;69(6):1557–65.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Dr Jones has conducted trials with trabectedin, sponsored by Johnson and Johnson. All other authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, University of Washington, 825 Eastlake Avenue East, Seattle, WA, USA

    Brett A. Schroeder, Eve T. Rodler, Elizabeth T. Loggers, Seth M. Pollack & Robin L. Jones

Authors
  1. Brett A. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eve T. Rodler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth T. Loggers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seth M. Pollack
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robin L. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin L. Jones.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schroeder, B.A., Rodler, E.T., Loggers, E.T. et al. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol 30, 501 (2013). https://doi.org/10.1007/s12032-013-0501-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0501-3

Keywords

Search

Navigation